simendan has been researched along with Experimental Mammary Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreadou, I; Chavdoula, E; Cokkinos, DV; Davos, CH; Efentakis, P; Farmakis, D; Gioti, K; Iliodromitis, EK; Klinakis, A; Kostomitsopoulos, N; Papapetropoulos, A; Sanoudou, D; Sigala, F; Suter, T; Tasouli, A; Tenta, R; Varela, A; Wenzel, P | 1 |
1 other study(ies) available for simendan and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy.
Topics: Animals; Antibiotics, Antineoplastic; Calcium Signaling; Calcium-Binding Proteins; Cardiotoxicity; Cardiovascular Agents; Cells, Cultured; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart Diseases; Male; Mammary Neoplasms, Experimental; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Myocardial Contraction; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Proto-Oncogene Proteins c-akt; Rats, Wistar; Simendan; Time Factors | 2020 |